The Indonesia generic drug market size reached USD 5.0 Billion in 2024 . Looking forward, IMARC Group expects the market to reach USD 9.9 Billion by 2033 , exhibiting a CAGR of 7.87% during 2025–2033 . Market growth is driven by government initiatives to improve healthcare access, the expansion of Indonesia's National Health Insurance (JKN) program, and increasing demand for cost-effective treatments. The rise in chronic diseases, along with growing awareness of affordable alternatives to branded drugs, further supports market expansion.

For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/indonesia-generic-drug-market/requestsample

Key Highlights

• Market Size (2024): USD 5.0 Billion
• Forecast (2033): USD 9.9 Billion
• CAGR (2025–2033): 7.87%
• Growth Drivers: Expansion of universal healthcare coverage, affordability of generic medicines, and rising chronic disease prevalence.
• Key Trends: Increasing penetration of biosimilars, investment in local manufacturing facilities, and digital distribution through e-pharmacies.
• Key Companies: Kalbe Farma, Kimia Farma, Dexa Medica, Sanbe Farma, Indo Farma, and multinational players with generic portfolios in Indonesia.

How Is AI Transforming the Generic Drug Market in Indonesia?

• Drug Discovery & Development: AI-driven simulations speeding up formulation research for generics.
• Regulatory Compliance: AI tools improving pharmacovigilance and documentation for faster approvals.
• Supply Chain Optimization: Machine learning enhancing demand forecasting and distribution efficiency.
• E-Pharmacy Integration: AI-powered platforms personalizing patient engagement and improving medicine adherence.

Key Market Trends and Drivers

• Government Support: JKN program driving demand for affordable medicines.
• Patent Expirations: Expiry of branded drugs creating opportunities for generics.
• Local Manufacturing: Investments in domestic pharmaceutical plants reducing import dependence.
• Digital Health Expansion: Growth of telemedicine and e-pharmacies boosting generic drug accessibility.
• Rising Chronic Diseases: Increasing prevalence of diabetes, cardiovascular diseases, and oncology cases.

Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=17019&flag=C

Market Segmentation

The report has segmented the market into the following categories:

Therapy Area Insights:

• Central Nervous System
• Cardiovascular
• Dermatology
• Genitourinary/Hormonal
• Respiratory
• Rheumatology
• Diabetes
• Oncology
• Others

Drug Delivery Insights:

• Oral
• Injectables
• Dermal/Topical
• Inhalers

Distribution Channel Insights:

• Retail Pharmacies
• Hospital Pharmacies

Regional Insights:

• Java
• Sumatra
• Kalimantan
• Sulawesi
• Others

Latest Developments in the Industry

• February 2025: Kalbe Farma announced expansion of its generic drug portfolio in oncology and cardiovascular segments.
• April 2025: Dexa Medica partnered with a local hospital network to improve distribution of affordable generics in rural areas.
• June 2025: Kimia Farma launched AI-enabled e-pharmacy services to streamline generic drug prescriptions and home delivery.
• Ongoing Trend: Government pushing local manufacturers to produce more biosimilars for chronic disease treatment.

MENAFN20082025004122016232ID1109952299